<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122840">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02096172</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002</org_study_id>
    <nct_id>NCT02096172</nct_id>
  </id_info>
  <brief_title>Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA</brief_title>
  <acronym>UTOPIA</acronym>
  <official_title>Urine Toxicology With Pharmacogenomic Interpretation Assay: UTOPIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Renaissance RX</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Renaissance RX</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the impact of pharmacogenomic aspects of drug
      metabolism on the measurement of drug and drug metabolites on urine drug testing (UDT).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort</study_design>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>Influence of CYP450 drug metabolism on quantitative UDT</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Occurrence of genetically-determined abnormal metabolism of drugs tested with UDT, classified as genetic effects on metabolism (GEM) + for rapid metabolizers, GEM 0 for normal metabolizers, and GEM - for slow metabolizers.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of illicit drugs detected on UDT and the GEM classification associated with these medications</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-prescribed drugs detected on UDT and the GEM classification associated with these medications</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>False positive immunoassay results, defined as positive immunoassay concurrent with negative quantitative testing</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of target drug regimen changes by the treating physician due to pharmacogenomic test results</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of illicit drug changes by the subject due to UDT results, as observed at the time of repeat UDT</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of non-prescribed drug changes by the subject due to UDT results, as detected at the time of repeat UDT</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200000</enrollment>
  <condition>Urine Toxicology</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male and female subjects who are considered candidates for UDT.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to provide written informed consent

          -  Pharmacogenomic testing within the last 60 days

          -  Planned UDT

        Exclusion Criteria:

          -  Subject has chronic renal dysfunction, Chronic Kidney Disease Stage 4 or 5

          -  Subject has a history of abnormal hepatic function within the last 2 years (INR &gt;1.2
             not attributable to anticoagulant medications, AST or ALT &gt;1.5x normal, or suspected
             cirrhosis)

          -  Subject has a history of malabsorption (short gut syndrome);

          -  Subject has a history of any gastric or small bowel surgery;

          -  Subject is currently hospitalized;

          -  Subject is currently receiving intravenous medication.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 21, 2014</lastchanged_date>
  <firstreceived_date>March 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
